News in brief - May 2014

Other new launches, licence changes and updates relevant to general practice.

Administration of parathyroid hormone in postmenopausal women with osteoporosis (pictured) has been shown to reduce the risk of fracture | SCIENCE PHOTO LIBRARY
Administration of parathyroid hormone in postmenopausal women with osteoporosis (pictured) has been shown to reduce the risk of fracture | SCIENCE PHOTO LIBRARY
  • Preotact, a parathyroid hormone injection licensed for the treatment of postmenopausal osteoporosis in women at high risk of fractures, is currently unavailable in the UK. No alternative parathyroid hormone preparation is available.
  • Actavis has launched Reltebon, a prolonged-release oxycodone tablet for the treatment of severe pain in patients from 12 years.
  • The NMDA antagonist memantine is now available as a generic tablet for the treatment of moderate to severe Alzheimer's dementia.

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...